Aspirin Therapy in Pericardial Effusion

Indications and Recommendations

The European Society of Cardiology recommends aspirin as the first-line anti-inflammatory agent for post-myocardial infarction pericarditis, with a Class I recommendation (Level C evidence) 3, 4
Aspirin is recommended as first-choice anti-inflammatory therapy for pericardial effusion associated with pericarditis, particularly in post-myocardial infarction pericarditis 1, 2
For pericardial effusion associated with systemic inflammation or pericarditis, aspirin/NSAIDs plus colchicine are recommended as first-line therapy, according to the European Heart Journal 5

The European Heart Journal demonstrates antiplatelet effects of aspirin for doses up to 1.5 g/day in the treatment of pericardial conditions 4
Aspirin plus colchicine may be considered for patients with persistent symptoms requiring more than supportive care, as recommended by the European Society of Cardiology 3

Early post-AMI pericarditis is a marker of larger infarct size but does not have independent prognostic significance, according to the European Heart Journal 3
Timely primary percutaneous coronary intervention may reduce the occurrence of post-AMI pericarditis, as reported in the European Heart Journal 4
Late post-AMI pericarditis (Dressler syndrome) is rare (<1%) in the era of primary percutaneous coronary intervention, according to the European Heart Journal 4
Anti-inflammatory therapy, including aspirin, is recommended in patients with post-cardiac injury syndromes to hasten symptom remission and reduce recurrences (Class I, Level B), as recommended by the European Heart Journal 2, 6

In postoperative pericardial effusions, NSAIDs like diclofenac have been shown to be ineffective and may increase risk of side effects, according to the European Heart Journal 1
For cardiac tamponade occurring in the first hours after cardiac surgery, surgical reintervention is mandatory rather than medical therapy, as reported in the European Heart Journal 1

Follow-up should be based on evaluation of symptoms, echocardiographic assessment of effusion size, and monitoring of inflammatory markers, as recommended by the European Heart Journal 5